Secondary malignancies

Current Opinion in Hematology

Volumn 3, Issue 6, 1996, Pages 466-470

  Socié, Gérard ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW TRANSPLANTATION; EPSTEIN BARR VIRUS; HUMAN; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SECOND CANCER; SOLID TUMOR; STEM CELL TRANSPLANTATION;

EID: 0029962511     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603060-00011     Document Type: Review

References (46)

1. Socié G, Henry-Amar M, Devergie A, Esperou-Bourdeau H, Ribaud P, Traineau R, Gluckman E: Malignant diseases after allogeneic bone marrow transplantation: an updated overview. Nouv Rev Fr Hematol 1994, 36:S75-S77.
2. Socié G, Kolb HJ, Ljungman P: Malignant disease after allogeneic bone marrow transplantation: the case for assessment of risk factors. Br J Haematol 1992, 80:427-430.
3. Witherspoon RP, Deeg HJ, Storb R: Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation 1994, 57:1413-1418.
4. Socié G, Kolb HJ: Malignant diseases after bone marrow transplantation: the case for tumor banking and continued reporting to registries. Bone Marrow Transplant 1995, 16:493-495.
5. Sobocinski KA, Rowlings PA, Curtis RE, Socié G, Shriner DA, Horowitz MM for the International Bone Marrow Transplant REgistry (IBMTR): Solid tumors developing after allogeneic bone marrow transplantation. Blood 1995, 86(suppl 1):460a.
6. Kolb HJ, Duell T, Socié G, Van Lint MT, Carreras E, Tichelli A, Ljungman P, Jacobsen N, Apperley JF, Hertenstein B, Weiss M, Nekolla E, Goldstone AH on behalf of the EBMT: New malignancies in patients surviving more than 5 years after marrow transplantation Blood 1995, 86(suppl 1):460a.
7. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossatibellani F, Meadows AT: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996, 334:745-751.
8. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Schulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ: Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long term analysis of risk factors and outcome. Blood 1996, 87:3625-3632.
9. Travis LB, Weeks J, Curtis RE, Chaffey JT, Stovall M, Banks PM, Boice JD: Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol 1996, 14:565-571.
10. Donaldson SS, Hancock SL: Second cancers after Hodgkin's disease in childhood. N Engl J Med 1996, 334:792-794. This editorial highlights specific statistical and methodologic aspects of the study of secondary malignancies. Although this paper discuss the results of a paper dealing with secondary cancer in conventionally treated Hodgkin's disease in childhood, most of the statistical aspects also applied to secondary neoplasms following hematopoietic stem cell transplantation.
11. Brown SA, Bashey A, Schey SA: Donor cell leukaemia: an unresolved problem. Eur J Haematol 1995, 54:198-199.
12. Lowsky R, Fyles G, Minden M, Lipton J, Meharchand J, Tejpar I, Zipursky A, Messner H: Detection of donor cell derived acute myelogenous leukaemia in a patient transplanted for chronic myelogenous leukaemia using fluorescence in situ hybridization. Br J Haematol 1996, 93:163-165.
13. Taylor P, Jackson GH, Lennard A, Hamilton PJ, Proctor SJ: Low frequency of myelodysplasia after autologous bone marrow transplantation. Lancet 1995, 345:1248-1249.
14. Kumar L: Secondary leukaemia after autologous bone marrow transplantation. Lancet 1995, 345:810.
15. Bhatia S, Ramsay NKC, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, Robison LL, Miller JS, Neglia JP: Malignant neoplasms following bone marrow transplantation. Blood 1996, 87:3633-3639. The Minneapolis group survey on secondary malignancy. This study includes 2150 patients and provides an estimate of the incidence and risk factors for the three main secondary malignancies, ie, leukemia (after autotransplantation), lymphoma/BCLPD (after allotransplantation) and solid tumors (after allo- and autotransplantation).
16. Roman-Unfer S, Bitran JD, Hanauer S, Johnson L, Rita D, Booth C, Chen K: Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer. Bone Marrow Transplant 1995, 16:163-168.
17. Pedersen-Bjergaad J, Pedersen M, Roulston D, Philip P: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995, 86:3542-3552.
18. Gale RE, Bunch C, Moir DJ, Patterson KG, Goldstone AH, Linch DC: Demonstration of developing myelodysplasia/acute myeloid leukaemia in haematologically normal patients after high-dose chemotherapy and autologous bone marrow transplantation using X-chromosome inactivation patterns. Br J Haematol 1996, 93:53-58.
19. Leblond V, Sutton L, Dorent R, Davi F, Bitker MO, Gabarre J, Charlotte F, Ghoussoub JJ, Fourcade C, Fischer A, Gandjbakhch I, Binet JL, Raphael M: Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995, 13:961-968.
20. Shepherd JD, Gascoyne RD, Barnett MJ, Coghlan D, Phillips GL: Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 1995, 15:639-641.
21. Frank D, Cesarman E, Liu YF, Michler RE, Knowles DM: Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 1995, 85:1396-1403.
22. Klein C, Rothenberger S, Niemeyer C, Bachmann E, Odermatt B, Böhm N, Brandis M, Knecht H: EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. Br J Haematol 1995, 91:938-940.
23. Kenacy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener M, Storch GA: Epstein-Barr virus DNA in peripheral blood leukocytes of patients with post-transplant lymphoproliferative disease. Transplantation 1995, 60:547-554.
24. Rooney CM, Smith CA, Ng CYC, Loftin SK, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345:9-13. Describes the use of EBV-specific cytotoxic T-lymphocyte cell lines to prevent or control BCLPD in 10 high-risk patients. In three patients showing signs of EBV reactivation (as assessed by semiquantitative PCR) EBV DNA concentrations returned to normal control range following immunotherapy, and a complete resolution of an immunoblastic lymphoma was demonstrated in a patient. These cytotoxic T-lymphocyte lines, which had been genetically marked, were demonstrated to persist for at least 10 weeks after administration.
25. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castromalaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O'Reilly RJ: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191.
26. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ: Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J Exp Med 1996, 183:1215-1228. The ability of EBV-specific cytotoxic cell lines to preferentially localize to and infiltrate EBV-positive tumors bearing donor HLA antigens and thereafter induce targeted regression of the disease is demonstrated in the SCID human/mouse model.
27. Schouten HC, Hopman AHN, Haesevoets AM, Arends JW: Large-cell anaplastic non-Hodgkin's lymphoma originating in donor cells after allogenic bone marrow transplantation. Br J Haematol 1995, 91:162-166.
28. André M, Henry-Amar M, Blaise D, Colombar P, Fleury J, Milpied N, Cahn JY, Pico JL, Bastion Y, Kuentz M, Biron P, Fermé C, Gisselbrecht C for the SFGM Hopital Saint Louis. Paris, France: Incidence of second cancers (SC) and causes of death after autologous stem cell transplantation (ASCT) for Hodgkin's disease (HD). Blood 1995, 86(suppl 1):640a.
29. Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, Sullivan KM, Gluckman E, Storb R: Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996, 87:386-392. This analysis of 700 patients who underwent allogeneic transplantation for aplastic anemia and Fanconi's anemia confirmed irradiation, increasing age, and diagnosis of Fanconi's anemia as potent risk factors for solid tumor. Furthermore, it showed an increased risk in patients who were treated with azathioprine for chronic graft-versus-host disease.
30. Socié G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, Mccann SR, Frickhofen N, Vantveerkorthof E, Gluckman E: Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993, 329:1152-1157.
31. Gamelin E, Francois S, Guyetant S, Rousselet MC, Duchatelard PP, Coindre JM, Ifrah N: Peripheral primitive neuroectodermal tumour after allogeneic bone marrow transplantation. Br J Haematol 1995, 91:935-937.
32. Lipton JH, Messner HA, Dolan SP: Secondary cancer after syngeneic bone marrow transplant. Bone Marrow Transplant 1995, 16:491-492.
33. Helg C, Adatto M, Salomon D, Roux E, Miralbell R, Chapuis B, Saurat JH: Kaposi's sarcoma following allogeneic bone marrow transplantation. Bone Marrow Transplant 1994, 14:999-1001.
34. Gluckman E, Parquet N, Scieux C, Deplanche M, Traineau R, Betheau P, Morinet F: KS-associated herpesvirus-like DNA sequences after allogeneic bone-marrow transplantation. Lancet 1995, 346:1558-1559.
35. Cohen J: Controversy: is KS really caused by new herpes virus? Science 1995, 268:1847-1848.
36. Roizman B: New viral footprints in Kaposi's sarcoma. N Engl J Med 1995, 332:1227-1228.
37. Levy JA: A new human herpes virus: KHSV or HHV8? Lancet 1995, 345:786.
38. Rady PL, Yen A, Rollefson JL, Orengo I, Bruce S, Hughes TK, Tyring SK: Herpesvirus-like DNA sequences in non-Kaposi sarcoma skin lesions of transplant patients. Lancer 1995, 345:1339-1340.
39. Iondon NJ, Farmery SM, Will EJ, Davison AM, Lodge JPA: Risk of neoplasia in renal transplant patients. Lancet 1995, 346:403-406.
40. Penn I: Malignant melanoma in organ allograft recipients. Transplantation 1996, 61:274-278.
41. Kieff E: Epstain-Barr virus: increasing evidence of a link to carcinoma. N Engl J Med 1995, 333:724-726.
42. Thomas DW, Ramsahoye B, Jasani B, Lim SH: Epstein-Barr virus in squamous cell carcinoma after renal transplantation. Transplantation 1995, 60:390-392.
43. Langston AA, Sanders JE, Deeg HJ, Crawford SW, Anasetti C, Sullivan KM, Flowers MED, Storb R: Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996, 92:758-765.
44. Flowers MED, Zanis J, Pasquini R, Deeg HJ, Ribeiro R, Longton G, Medeiros CR, Doney K, Sanders J, Bryant E, Hansen J, Sullivan KM, Appelbaum F, Thomas ED, Storb R: Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. Br J Haematol 1996, 92:699-706.
45. Sorensen TIA: Is there an inherited general susceptibility to cancer? N Engl J Med 1995, 333:1633-1635.
46. Heslop HE, Catherine YC, Li C, Smith CA, Loftin SK, Krance RA, Brenner NK, Rooney CM: Long-term restoration of immunity against EBV infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med 1996, 8:661-555.